Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.44 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29405051 | 0.98 | CA12 (0.49) | CA1CA12CA9MAP1LC3BMAP1LC3A | |
| SCHEMBL14050068 | 0.98 | CA12 (0.49) | CA1CA12CA9MAP1LC3BMAP1LC3A | |
| SCHEMBL29419661 | 0.93 | CA12 (0.52) | CA1CA12CA9MAP1LC3BMAP1LC3A | |
| SCHEMBL17821546 | 0.93 | CA12 (0.52) | CA1CA12CA9MAP1LC3BMAP1LC3A | |
| SCHEMBL2199089 | 0.93 | CA12 (0.52) | CA1CA12CA9MAP1LC3BMAP1LC3A | |
| Hydrochloric Acid SCHEMBL11482111 | 0.92 | CA12 (0.45) | CA1CA12CA9MAP1LC3BMAP1LC3A | |
| Hydrochloric Acid SCHEMBL11470385 | 0.91 | CA1 (0.50) | CA1CA12CA9TDP1KDM4E | |
| SCHEMBL29544027 | 0.91 | CA1 (0.50) | CA1CA12CA9TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL29692762 | 0.90 | CA1 (0.49) | CA1CA12CA9TDP1KDM4E | |
| Hydrochloric Acid SCHEMBL11217796 | 0.89 | CA1 (0.49) | CA1CA12CA9MAP1LC3BMAP1LC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10238735-B2 | Controlled activation of complement components for use as endogenous adjuvant | PLS-DESIGN GMBH (DE) | 2019-03-26 | — | — | US | disclosed |
| EP-1644409-B1 | COMPLEMENT DEPLETION USING RECOMBINANT HUMAN C3-DERIVATIVES | PLS-DESIGN GMBH (DE) | 2016-12-21 | — | — | EP | disclosed |
| US-20130337045-A1 | CONTROLLED ACTIVATION OF COMPLEMENT COMPONENTS FOR USE AS ENDOGENOUS ADJUVANT | KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN (DE) | 2013-12-19 | — | — | US | disclosed |
| US-20130337044-A1 | MODULATION OF EFFECTOR T CELL RESPONSES BY LOCAL DEPLETION OF COMPLEMENT COMPONENT C3 | Helmholtz Zentrum Munchen Forschungszentrum fur Gesundheit und Umwelt GmbH (DE) | 2013-12-19 | — | — | US | disclosed |
| EP-2674168-A1 | Modulation of effector T cell responses by local depletion of complement component C3 | PLS-Design GmbH (DE) | 2013-12-18 | — | — | EP | disclosed |
| EP-2674167-A1 | Controlled activation of complement components for use as endogenous adjuvant | PLS-Design GmbH (DE) | 2013-12-18 | — | — | EP | disclosed |
| US-8119769-B2 | Complement depletion using recombinant human C-3 derivatives | PLS Design, GmbH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20090270324-A1 | COMPLEMENT DEPLETION USING RECOMBINANT HUMAN C-3 DERIVATIVES | KOLLN JOHANNA | 2009-10-29 | — | — | US | disclosed |
| US-7553931-B2 | Complement depletion using recombinant human C3-derivatives | PLS-DESIGN GMBH (DE) | 2009-06-30 | — | — | US | disclosed |
| US-20050079585-A1 | Complement depletion using recombinant human C3-derivatives | PLS DESIGN GMBH (DE) | 2005-04-14 | — | — | US | disclosed |